NCT03240328 The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
| NCT ID | NCT03240328 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Guangzhou 8th People's Hospital |
| Condition | HIV/AIDS |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2017-10-04 |
| Primary Completion | 2023-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2017-10-04 with a primary completion date of 2023-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.
Eligibility Criteria
Inclusion Criteria: 1. HIV infection confirmed. 2. Receiving cART more than 12 months. 3. HIV viral-load \< 50 copies/ml and CD4 cell count more than 350 cells/ul. 4. Without serious liver, heart, liver and kidney diseases. 5. The subjects know about the study and volunteer to attend the research and sign the informed consent. Exclusion Criteria: 1. With active HBV or HCV infection, or serious opportunistic infections. 2. With serious chronic disease such like diabetes, the mental illness,et al 3. History of suffering from pancreatitis during cART. 4. Pregnant or breast-fed. 5. With poor adherence. 6. Unable to complete follow up.
Contact & Investigator
Cai Weiping, Bachelor
PRINCIPAL INVESTIGATOR
Guangzhou 8th People's Hospital
Frequently Asked Questions
Who can join the NCT03240328 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying HIV/AIDS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03240328 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT03240328 currently recruiting?
Yes, NCT03240328 is actively recruiting participants. Contact the research team at llheliza@126.com for enrollment information.
Where is the NCT03240328 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT03240328 clinical trial?
NCT03240328 is sponsored by Guangzhou 8th People's Hospital. The principal investigator is Cai Weiping, Bachelor at Guangzhou 8th People's Hospital. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.